Anticancer research · 2026
Self-differentiated Dendritic Cells Presenting NY-ESO-1 Prime Cytotoxic T Cells for the Treatment of Multiple Myeloma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Samutpradit Danai, Areesawangkit Phurin, Hengswat Pranaidej, Chiraphapphaiboon Wannasiri, Phikulsod Ployploen, Choome Kornkan, Phanthaphol Nattaporn, Wutti-In Yupanun, Junking Mutita, Sukpanichnant Sanya, Chieochansin Thaweesak, Yenchitsomanus Pa-Thai
Аннотация
BACKGROUND/AIM: Multiple myeloma (MM) remains incurable due to relapse and therapeutic resistance. This study evaluated the cancer-testis antigen NY-ESO-1 as a target for T-cell-based immunotherapy and assessed the potential of a self-differentiated monocyte-derived dendritic cell platform expressing NY-ESO-1 (SD-DC-NY) to activate T-lymphocytes against MM in vitro.
MATERIALS AND METHODS: NY-ESO-1 expression was assessed by immunohistochemistry (IHC) in 95 MM cases. A lentiviral tri-cistronic construct encoding GM-CSF, IL-4, and NY-ESO-1 was used to generate SD-DC-NY. Autologous T-lymphocytes were activated with SD-DC-NY and tested against NY-ESO-1-positive U266 and NY-ESO-1-negative JJN-3 cells. Cytotoxicity (annexin V/PI) and interferon-gamma (IFN-γ) secretion (ELISA) were measured. Statistical significance was set at α=0.05 using two-sided tests.
RESULTS: NY-ESO-1 was detected in 17.9% (17/95) of MM samples. SD-DC-NY showed DC maturation comparable to conventional cytokine-generated DCs. SD-DC-NY-activated T-lymphocytes induced higher apoptosis of U266 cells versus controls (p<0.0001) and secreted more IFN-γ (p<0.05).
CONCLUSION: SD-DC-NY effectively primes cytotoxic T-lymphocytes and enhances antitumor activity against NY-ESO-1-positive MM cells, supporting NY-ESO-1 as an immunotherapeutic target and highlighting SD-DC-NY as a promising platform for MM immunotherapy.
MATERIALS AND METHODS: NY-ESO-1 expression was assessed by immunohistochemistry (IHC) in 95 MM cases. A lentiviral tri-cistronic construct encoding GM-CSF, IL-4, and NY-ESO-1 was used to generate SD-DC-NY. Autologous T-lymphocytes were activated with SD-DC-NY and tested against NY-ESO-1-positive U266 and NY-ESO-1-negative JJN-3 cells. Cytotoxicity (annexin V/PI) and interferon-gamma (IFN-γ) secretion (ELISA) were measured. Statistical significance was set at α=0.05 using two-sided tests.
RESULTS: NY-ESO-1 was detected in 17.9% (17/95) of MM samples. SD-DC-NY showed DC maturation comparable to conventional cytokine-generated DCs. SD-DC-NY-activated T-lymphocytes induced higher apoptosis of U266 cells versus controls (p<0.0001) and secreted more IFN-γ (p<0.05).
CONCLUSION: SD-DC-NY effectively primes cytotoxic T-lymphocytes and enhances antitumor activity against NY-ESO-1-positive MM cells, supporting NY-ESO-1 as an immunotherapeutic target and highlighting SD-DC-NY as a promising platform for MM immunotherapy.